5

10

15

20

25

30

## WHAT IS CLAIMED IS:

1. A method of inhibiting a protein-protein interaction comprising:

identifying a first sequence of a first protein that binds to a second protein, wherein said first sequence is between three and ten consecutive amino acids that bind to said second protein;

providing a peptide agent comprising a peptide in amide form having a second sequence identical to said first sequence; and

contacting said peptide agent with said second protein so as to inhibit said protein-protein interaction.

- 2. The method of Claim 1, wherein said first and second proteins are the same.
- 3. The method of Claim 1, wherein said first and second protein are selected from the group consisting of p24, a bacterial toxin protein, actin,  $\beta$ -amyloid, and tubulin.
- 4. The method of Claim 1, wherein said first protein is a transcriptional activator or transcriptional repressor.
- 5. The method of Claim 1, wherein said first protein is a bacterial toxin protein.
  - 6. The method of Claim 1, wherein said first protein is actin.
  - 7. The method of Claim 1, wherein said first protein is  $\beta$ -amyloid.
  - 8. The method of Claim 1, wherein said first protein is tubulin.
  - 9. A method of inhibiting a protein-protein interaction comprising:

identifying a first sequence of a first protein that binds to a second protein, wherein said first sequence is three consecutive amino acids that bind to said second protein;

providing a tripeptide amide having a second sequence identical to the first sequence; and

contacting said tripeptide amide with said second protein so as to inhibit said protein-protein interaction.

10. The method of Claim 9, wherein said first and second proteins are the same.

-76-

5

10

15

20

25

30

- 11. The method of Claim 9, wherein said first and second protein are selected from the group consisting of p24, a bacterial toxin protein, actin,  $\beta$ -amyloid, and tubulin.
- 12. The method of Claim 9, further comprising measuring the inhibition of said protein-protein interaction by measuring the binding of said tripeptide amide to said second protein.
- 13. The method of Claim 9, wherein said first protein is a transcriptional activator or transcriptional repressor.
- 14. The method of Claim 9, wherein said first protein is a bacterial toxin protein.
  - 15. The method of Claim 9, wherein said first protein is actin.
  - 16. The method of Claim 9, wherein said first protein is  $\beta$ -amyloid.
  - 17. The method of Claim 7, wherein said first protein is tubulin.
  - 18. A method of making a pharmaceutical comprising:

identifying a first sequence of a first protein that binds to a second protein, wherein said first sequence is between three and ten consecutive amino acids that bind to said second protein; and

providing a peptide agent comprising a peptide in amide form having a second sequence identical to said first sequence.

- 19. The method of Claim 18, wherein said first protein is a transcriptional activator or transcriptional repressor.
- 20. The method of Claim 18, wherein said first protein is a bacterial toxin protein.
  - 21. The method of Claim 18, wherein said first protein is actin.
  - 22. The method of Claim 18, wherein said first protein is  $\beta$ -amyloid.
  - 23. The method of Claim 18, wherein said first protein is tubulin.
  - 24. A method of making a pharmaceutical comprising:

identifying a first sequence of a first protein that binds to a second protein, wherein said first sequence is three consecutive amino acids that bind to said second protein; and

providing a tripeptide amide having a second sequence identical to the first sequence.